Abstract 

The 10th Cardiovascular Outcomes Research Summit (CVOT): Congress on Cardiovascular, Renal and Metabolic Outcomes was held online on 5–6 December 2024. This year, discussions on cardiovascular (CV) and renal research focused on the latest results from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP- HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finarenon (FINEARTS-HF). These studies demonstrate significant progress in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The Congress also included sessions on new and existing therapies for heart failure with preserved ejection fraction, CKD, and obesity; guidelines for the treatment of CKD and metabolic-associated steatosis (MAS); cross-organ interactions and the development of cardiorenometabolic syndrome (CRMS); precision medicine and personalized treatment of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes mellitus (DM) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (ADI); cardiac autonomic neuropathy (CAN) and the diabetic heart; the role of primary care in the early detection, prevention and treatment of diseases associated with CKD. The contribution of environmental plastic pollution to CVD risk, the growing understanding of the efficacy and safety of incretin therapy in the treatment of CKD, and the latest evidence on incretin-based nutritional strategies in the treatment of CKD were also topics of interest to a broad audience of endocrinologists, diabetologists, cardiologists, nephrologists, and primary care physicians who actively participated in the online discussions. The 11th CVOT Summit will be held online on November 20–21, 2025 (http://www.cvot.org).
Keywords: Cardiovascular disease, Chronic kidney disease, CGM, CKM, Diabetes, Finerenone, GLP-1 RA, Guidelines, Heart failure, MASLD, Obesity, SGLT2 inhibitor, Tirzepatide.